<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.ukri.org:80/organisation/5DDCCDE6-59AD-4755-85D5-7A124AFAEF1D"><gtr:id>5DDCCDE6-59AD-4755-85D5-7A124AFAEF1D</gtr:id><gtr:name>Roslin Cells Ltd</gtr:name><gtr:address><gtr:line1>Roslin Biocentre</gtr:line1><gtr:postCode>EH25 9PP</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/4F1D2F3A-756D-4BC2-9E81-091D0356FECB"><gtr:id>4F1D2F3A-756D-4BC2-9E81-091D0356FECB</gtr:id><gtr:name>TAP Biosystems</gtr:name><gtr:address><gtr:line1>York Way</gtr:line1><gtr:line2>Royston</gtr:line2><gtr:line3>Herts</gtr:line3><gtr:postCode>SG8 5WY</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AF6B2D5D-08D1-4920-96A3-4913CBBD0403"><gtr:id>AF6B2D5D-08D1-4920-96A3-4913CBBD0403</gtr:id><gtr:name>Douglas Connect</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/20A7D9B9-9D83-49FA-9E48-AB596B9E1D7D"><gtr:id>20A7D9B9-9D83-49FA-9E48-AB596B9E1D7D</gtr:id><gtr:name>International Stem Cell Forum (ISCF)</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/22F01640-ABE4-47E4-AD36-61CB99D205A4"><gtr:id>22F01640-ABE4-47E4-AD36-61CB99D205A4</gtr:id><gtr:name>Cellectis</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/0B739936-E847-4D0C-8C2A-AE0C504D9F9A"><gtr:id>0B739936-E847-4D0C-8C2A-AE0C504D9F9A</gtr:id><gtr:name>Lausanne University</gtr:name><gtr:address><gtr:line1>Lausanne University</gtr:line1><gtr:line2>Dorigny</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/AC164095-49BC-4450-8225-CC32DB237D60"><gtr:id>AC164095-49BC-4450-8225-CC32DB237D60</gtr:id><gtr:name>Asymptote</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.ukri.org:80/organisation/6D89F092-22C9-46EF-B160-67F481A1B7D3"><gtr:id>6D89F092-22C9-46EF-B160-67F481A1B7D3</gtr:id><gtr:name>Leadscope Inc.</gtr:name></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/EDB67137-AF95-475C-954C-8EA1517069D6"><gtr:id>EDB67137-AF95-475C-954C-8EA1517069D6</gtr:id><gtr:name>Nat Inst for Bio Standards and Control</gtr:name><gtr:department>UNLISTED</gtr:department><gtr:address><gtr:line1>Blanche Lane</gtr:line1><gtr:line2>South Mimms</gtr:line2><gtr:line4>Potters Bar</gtr:line4><gtr:line5>Hertfordshire</gtr:line5><gtr:postCode>EN6 3QG</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/EDB67137-AF95-475C-954C-8EA1517069D6"><gtr:id>EDB67137-AF95-475C-954C-8EA1517069D6</gtr:id><gtr:name>Nat Inst for Bio Standards and Control</gtr:name><gtr:address><gtr:line1>Blanche Lane</gtr:line1><gtr:line2>South Mimms</gtr:line2><gtr:line4>Potters Bar</gtr:line4><gtr:line5>Hertfordshire</gtr:line5><gtr:postCode>EN6 3QG</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/5DDCCDE6-59AD-4755-85D5-7A124AFAEF1D"><gtr:id>5DDCCDE6-59AD-4755-85D5-7A124AFAEF1D</gtr:id><gtr:name>Roslin Cells Ltd</gtr:name><gtr:address><gtr:line1>Roslin Biocentre</gtr:line1><gtr:postCode>EH25 9PP</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/4F1D2F3A-756D-4BC2-9E81-091D0356FECB"><gtr:id>4F1D2F3A-756D-4BC2-9E81-091D0356FECB</gtr:id><gtr:name>TAP Biosystems</gtr:name><gtr:address><gtr:line1>York Way</gtr:line1><gtr:line2>Royston</gtr:line2><gtr:line3>Herts</gtr:line3><gtr:postCode>SG8 5WY</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AF6B2D5D-08D1-4920-96A3-4913CBBD0403"><gtr:id>AF6B2D5D-08D1-4920-96A3-4913CBBD0403</gtr:id><gtr:name>Douglas Connect</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD"><gtr:id>C7FBE408-C743-4AAC-9BC6-65E14BC8D2FD</gtr:id><gtr:name>Karolinska Institute</gtr:name><gtr:address><gtr:line1>Administration</gtr:line1><gtr:line4>Stockholm</gtr:line4><gtr:postCode>SE-171 77</gtr:postCode><gtr:region>Outside UK</gtr:region><gtr:country>Sweden</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/48990B2D-6D88-4205-B3F4-58863EA78D0D"><gtr:id>48990B2D-6D88-4205-B3F4-58863EA78D0D</gtr:id><gtr:name>National Institute of Health and Medical Research (INSERM)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/20A7D9B9-9D83-49FA-9E48-AB596B9E1D7D"><gtr:id>20A7D9B9-9D83-49FA-9E48-AB596B9E1D7D</gtr:id><gtr:name>International Stem Cell Forum (ISCF)</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/22F01640-ABE4-47E4-AD36-61CB99D205A4"><gtr:id>22F01640-ABE4-47E4-AD36-61CB99D205A4</gtr:id><gtr:name>Cellectis</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/0B739936-E847-4D0C-8C2A-AE0C504D9F9A"><gtr:id>0B739936-E847-4D0C-8C2A-AE0C504D9F9A</gtr:id><gtr:name>Lausanne University</gtr:name><gtr:address><gtr:line1>Lausanne University</gtr:line1><gtr:line2>Dorigny</gtr:line2><gtr:region>Outside UK</gtr:region><gtr:country>Switzerland</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/AC164095-49BC-4450-8225-CC32DB237D60"><gtr:id>AC164095-49BC-4450-8225-CC32DB237D60</gtr:id><gtr:name>Asymptote</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/6D89F092-22C9-46EF-B160-67F481A1B7D3"><gtr:id>6D89F092-22C9-46EF-B160-67F481A1B7D3</gtr:id><gtr:name>Leadscope Inc.</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/38DD21D0-97EE-4180-A444-FF579BF141B6"><gtr:id>38DD21D0-97EE-4180-A444-FF579BF141B6</gtr:id><gtr:firstName>Glyn</gtr:firstName><gtr:surname>Stacey</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=G1001045"><gtr:id>27A6C462-DFA3-4755-B4EB-F8D025820015</gtr:id><gtr:title>UK Stem Cell Bank - Third Phase</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G1001045</gtr:grantReference><gtr:abstractText>In 2002 the UK Government established that a Bank of human embryonic cell lines should be established to oversee the use of these cells to ensure that any cells of this type, used in the UK were obtained ethically and only used in research for the benefit of treatment of serious human disease. 
In addition the Bank should provide access to quality-controlled stocks of these cell lines to provide a high quality international resource in support of the UK s stem cell community and to further the use of these cells in regenerative medicine. Such a role for the Bank in supporting the move of stem cell therapies from the laboratory to the bedside was confirmed to be a key element in the UK Stem Cell Initiative Report prepepared by Sir John Pattison and accepted by the Government. 
In the next phase of funding (Phase III) the Bank aims to sustain and develop its position as the foremost repository of ethically-sourced and well characterised stocks of human stem cell lines banked to international quality standards. Whilst in Phase II the primary focus of the Bank was on academic research, Phase III will see the Bank coordinating more closely with scientific programmes translating research developments into therapeutic applications, the regenerative medicine clinical community and those developing human cell culture models to improve the efficiency of development of new drugs to reduce costs and increase patient safety. The Bank will continue to develop its international role in supporting the development of stem cell therapy through:
? the provision of quality-assured and safety tested cell lines and other products supporting researchers and clinical applications;
? its continued lead on best practice and the setting of international consensus standards for the delivery of high quality and safe stem cells;
? its developing training programme for stem cell scientists, technical staff and quality assurance personnel in support of the UK s developing regenerative medicine industry;
? its scientific collaborations and internal research programme to establish robust methodologies for cell expansion, differentiation, preservation and characterisation which will improve the qulity of materials supplied for research and provide improved methodological approaches for clincial application.
It is intended that the Bank will now implement its position as a national resource and international centre of expertise in support of the development of regenerative medicines and product safety in the UK.</gtr:abstractText><gtr:technicalSummary>Following competitive tender to establish the UK Stem Cell Bank (the Bank) in 2002, and successful delivery of all objectives for Phase 1 funding (2003-2005), a Phase 2 grant for this project (2006-2011) was secured by the National Institute for Biological Standards and Control (now a centre of the Health Protection Agency). All objectives are again being met on time and within budgets agreed with sponsors. A description of progress made in Phase 2 is given in the attached Progress Report and in the Annual Reports on its website at www.ukstemcellbank.org.uk.

During Phase III, the Bank will focus its activities on supporting the key public health aspects of stem cell therapy and development of human cell-based assays in safety testing of products. Phase 3 will see the Bank coordinating more closely with translational scientific programmes, thus making the Bank?s resources available to provide broad support for the UK?s developing the regenerative medicine clinical community, both academic and commercial,and those developing models for in vitro toxicology and drug discovery. The Bank will work in closer coordination with commercial partners whilst retaining its neutral position and capability to support all stakeholders in this field. 

At the same time, the Bank aims to sustain and develop its position as the foremost repository of ethically-sourced and well characterised stocks of human stem cell lines banked to international quality standards. 

The Bank will continue to develop its international role in supporting the development of stem cell therapy through:

? the provision of quality-assured and safety tested cell lines and ancillary products;

? its continued lead on best practice and the setting of international consensus standards;

? its developing training programme for stem cell scientists, technical staff and quality assurance personnel;

? its scientific collaborations and internal research programme to establish robust methodologies for cell expansion, differentiation, preservation and characterisation.



Furthermore, the Bank proposes to implement its cost recovery plan to progressively reduce its dependence on Research Council funding during the period of Phase 3. 



These aims are intended to sustain the leading International profile of the Bank whilst increasing its support for commercial delivery of products and at the same time progressing towards substantially removing the burden of funding which has fallen on its sponsors.</gtr:technicalSummary><gtr:fund><gtr:end>2014-05-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2011-04-04</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>3338803</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>International Stem Cell Forum (ISCF)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>International Stem Cell Initiative</gtr:description><gtr:id>89C89208-5A2B-44CE-B71A-7CA2AF263326</gtr:id><gtr:impact>Three publications in In Vitro (2010) and Nat Biotech (2007 and 2012)
Stacey GN. (in press) Stem Cell Banking: A Global Overview. In: Stem Cell Banking: Methods and Protocols, Human Press, Springer Science +Business Media LLC, USA.</gtr:impact><gtr:outcomeId>ScD7F5jaTAb-1</gtr:outcomeId><gtr:partnerContribution>three publications in In Vitro (2010) and Nature Biotech 2007 and in press</gtr:partnerContribution><gtr:piContribution>Carried out characterisation testing, supplied stockc of antibodies, crried out independednt qualification of poor performing media</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2006-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>National Institute of Health and Medical Research (INSERM)</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:department>Institute for Stem cell Therapy and Exploration of Monogenic diseases (I-Stem)</gtr:department><gtr:description>Scr&amp;amp;Tox</gtr:description><gtr:id>59EE7F55-333B-4BE8-9B18-3199CAAE068F</gtr:id><gtr:impact>Publications on quality control ad assays development 
Pistollato, F., Bremer-Hoffmann, S., Healy, L., Young, L. and Stacey, G. (2012) Standardisation of pluripotent stem cell cultures for toxicity testing, Expert Opinion On Drug Metabolism and Toxicology, 8(2):239-257.
Stacey GN, Coecke S, Price A, Healy L, Jennings P, Wilmes A, Pinset C, Sundstrom M. Myatt G. (2016) Ensuring the quality of stem cell derived models for toxicity testing. In: Validation of Alternative Methods for Toxicity Testing. Eds ESkes C and Whelan M. Springer. pp259-297.ISBN 978-3-319-33826-2</gtr:impact><gtr:outcomeId>mbUAuCoQp9B-1</gtr:outcomeId><gtr:partnerContribution>Development of differentiation protocols and translation into autmated HTP systems</gtr:partnerContribution><gtr:piContribution>Generation, banking and distribition of human pluripotent stem cell lines. Iisolation and distribution of iPSC lines as controls</gtr:piContribution><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Cellectis</gtr:collaboratingOrganisation><gtr:country>France, French Republic</gtr:country><gtr:description>Scr&amp;amp;Tox</gtr:description><gtr:id>9BD86FE2-A6B5-49D7-958B-2D1B21E7DE3A</gtr:id><gtr:impact>Publications on quality control ad assays development 
Pistollato, F., Bremer-Hoffmann, S., Healy, L., Young, L. and Stacey, G. (2012) Standardisation of pluripotent stem cell cultures for toxicity testing, Expert Opinion On Drug Metabolism and Toxicology, 8(2):239-257.
Stacey GN, Coecke S, Price A, Healy L, Jennings P, Wilmes A, Pinset C, Sundstrom M. Myatt G. (2016) Ensuring the quality of stem cell derived models for toxicity testing. In: Validation of Alternative Methods for Toxicity Testing. Eds ESkes C and Whelan M. Springer. pp259-297.ISBN 978-3-319-33826-2</gtr:impact><gtr:outcomeId>mbUAuCoQp9B-2</gtr:outcomeId><gtr:partnerContribution>Development of differentiation protocols and translation into autmated HTP systems</gtr:partnerContribution><gtr:piContribution>Generation, banking and distribition of human pluripotent stem cell lines. Iisolation and distribution of iPSC lines as controls</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>TAP Biosystems</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ESNATS</gtr:description><gtr:id>1C4F9248-F664-4F2B-9D07-B022C1F28E36</gtr:id><gtr:impact>Publication : P DeSousa, S Mcrae and G Stacey Pluripotent stem cells as cellular product for regenerative medicine. In : Regenerative Medicine , In: Pluripotent Stem Cells and the Liver. Ed. D Hay , Science Publishers (2012 in press).</gtr:impact><gtr:outcomeId>cC7DiCeEEj9-1</gtr:outcomeId><gtr:partnerContribution>Development of scale up and preservation protocols
Development of differentiation protocols</gtr:partnerContribution><gtr:piContribution>Comparison and validation of different stem cell differentiation protocols to obtain different neuronal cell types</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Asymptote</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>TSB Asymptote</gtr:description><gtr:id>203F827B-04D7-44C7-939D-D1D345B1E56C</gtr:id><gtr:impact>Initial feedback on the new device 
Workplan established. UKSCB organised 2 coordination meetings between this project and other TSB funded projects in related areas
Book chapter - Stacey, G., Healy, H., Mann, J., Hunt, CJ., and Morris, J. (2016) Fundamental Points to Consider in the Cryopreservation and Shipment of Cells for Human Application. Chapter 6. In: Bioprocessing for Cell- based Therapies. Ed. Che Connon, Wiley-Blackwell. pp167-186.</gtr:impact><gtr:outcomeId>fZZCXov2yci-2</gtr:outcomeId><gtr:partnerContribution>Complimentary work within the research programme at Roslin Cells and coordination with the manufacturer (Asymptote) on improvements to software and hardware to effect enrichment of viable cells .</gtr:partnerContribution><gtr:piContribution>Development of new preservation equipment and preservation profiles</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>ESNATS</gtr:description><gtr:id>D2E1509A-9E9F-49C9-A513-A84656CFC58A</gtr:id><gtr:impact>Publication : P DeSousa, S Mcrae and G Stacey Pluripotent stem cells as cellular product for regenerative medicine. In : Regenerative Medicine , In: Pluripotent Stem Cells and the Liver. Ed. D Hay , Science Publishers (2012 in press).</gtr:impact><gtr:outcomeId>cC7DiCeEEj9-3</gtr:outcomeId><gtr:partnerContribution>Development of scale up and preservation protocols
Development of differentiation protocols</gtr:partnerContribution><gtr:piContribution>Comparison and validation of different stem cell differentiation protocols to obtain different neuronal cell types</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Karolinska Institute</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>ToxBank</gtr:description><gtr:id>AEF0F0D8-531C-4DB7-BF0B-7E798EB4BE28</gtr:id><gtr:impact>Cross consotium collaboration on cell line quality control and poster preaetnations at SEURAT-1 meetings
Kohonen, P; Benfenati, E; Bower, D; Ceder, R; Crump, M; Cross, K; Grafstr&amp;ouml;m, R; Healey, L; Helma, C; Jeliazkova, N; Jeliazkov, V; Maggioni, S; Miller, S; Myatt, G; Rautenberg, M; Stacey, G; Willighagen, E; Wiseman, J; Hardy, B (2013) The ToxBank Data Warehouse: Supporting the Replacement of In Vivo Repeated Dose Systemic Toxicity Testing. Molecular Informatics. Special Issue: Advances in Computational Toxicology. 32; 47-63.
Public conference and workshop: Stem Cell Applications, Wellcome Trust, London, Nov 2015
Opentox workshop: Bridging strategies for stem cells, Rheinfelden, Germany, October 31st 2015.</gtr:impact><gtr:outcomeId>MWq6DKTUq83-3</gtr:outcomeId><gtr:partnerContribution>Overall construction of data warehouse and toxciology sections</gtr:partnerContribution><gtr:piContribution>Creation of biomaterials sections of data warehouse for the multiconsotium cluster SEURAT-1</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Roslin Cells Ltd</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>TSB Asymptote</gtr:description><gtr:id>8241B9C2-56C3-48CE-B40D-2D422F71E9C4</gtr:id><gtr:impact>Initial feedback on the new device 
Workplan established. UKSCB organised 2 coordination meetings between this project and other TSB funded projects in related areas
Book chapter - Stacey, G., Healy, H., Mann, J., Hunt, CJ., and Morris, J. (2016) Fundamental Points to Consider in the Cryopreservation and Shipment of Cells for Human Application. Chapter 6. In: Bioprocessing for Cell- based Therapies. Ed. Che Connon, Wiley-Blackwell. pp167-186.</gtr:impact><gtr:outcomeId>fZZCXov2yci-1</gtr:outcomeId><gtr:partnerContribution>Complimentary work within the research programme at Roslin Cells and coordination with the manufacturer (Asymptote) on improvements to software and hardware to effect enrichment of viable cells .</gtr:partnerContribution><gtr:piContribution>Development of new preservation equipment and preservation profiles</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Leadscope Inc.</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:description>ToxBank</gtr:description><gtr:id>513C73E7-4566-450F-9AC8-3D0DF2F8F5EA</gtr:id><gtr:impact>Cross consotium collaboration on cell line quality control and poster preaetnations at SEURAT-1 meetings
Kohonen, P; Benfenati, E; Bower, D; Ceder, R; Crump, M; Cross, K; Grafstr&amp;ouml;m, R; Healey, L; Helma, C; Jeliazkova, N; Jeliazkov, V; Maggioni, S; Miller, S; Myatt, G; Rautenberg, M; Stacey, G; Willighagen, E; Wiseman, J; Hardy, B (2013) The ToxBank Data Warehouse: Supporting the Replacement of In Vivo Repeated Dose Systemic Toxicity Testing. Molecular Informatics. Special Issue: Advances in Computational Toxicology. 32; 47-63.
Public conference and workshop: Stem Cell Applications, Wellcome Trust, London, Nov 2015
Opentox workshop: Bridging strategies for stem cells, Rheinfelden, Germany, October 31st 2015.</gtr:impact><gtr:outcomeId>MWq6DKTUq83-2</gtr:outcomeId><gtr:partnerContribution>Overall construction of data warehouse and toxciology sections</gtr:partnerContribution><gtr:piContribution>Creation of biomaterials sections of data warehouse for the multiconsotium cluster SEURAT-1</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>TSB Apopro</gtr:description><gtr:id>9121BBA8-1305-40F6-B790-34D37217CE4B</gtr:id><gtr:impact>progress on prototype</gtr:impact><gtr:outcomeId>VRtsQLVNEgm-1</gtr:outcomeId><gtr:partnerContribution>Development of product</gtr:partnerContribution><gtr:piContribution>Provide expert opinion</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International Stem Cell Forum (ISCF)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:department>International Stem Cell Initiative</gtr:department><gtr:description>International Stem Cell Banking Initiative</gtr:description><gtr:id>E0BB8C18-AC48-4310-BD8F-3FED60C3E22D</gtr:id><gtr:impact>Consensus on best practice in the procurement banking testing and release of hESC lines (2009)
Andrews et al., (2015) Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications. Regenerative Medicine. 10 (02s) doi: 10.2217/RME.14.93 
Stacey GN. (in press) Stem Cell Banking: A Global Overview. In: Stem Cell Banking: Methods and Protocols, Human Press, Springer Science +Business Media LLC, USA.</gtr:impact><gtr:outcomeId>WRmpnyo4P5u-2</gtr:outcomeId><gtr:partnerContribution>Consensus on best opractice (Andrews et al., Stem Cell Reports and Revs , Dec 2009). Stem cell bank self evaluation procedures (Stacey et al., Cell Stem Cell 2013). managing research data from stem cell lines (Isasi et al., Regen Med, 2012).</gtr:partnerContribution><gtr:piContribution>Led coordination of scientists and regulators from more than 20 countries and compiled reports and draft publications</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Lausanne</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>ESNATS</gtr:description><gtr:id>1CBA8061-BEB5-48C0-A5AC-7DFDA1D12CA8</gtr:id><gtr:impact>Publication : P DeSousa, S Mcrae and G Stacey Pluripotent stem cells as cellular product for regenerative medicine. In : Regenerative Medicine , In: Pluripotent Stem Cells and the Liver. Ed. D Hay , Science Publishers (2012 in press).</gtr:impact><gtr:outcomeId>cC7DiCeEEj9-2</gtr:outcomeId><gtr:partnerContribution>Development of scale up and preservation protocols
Development of differentiation protocols</gtr:partnerContribution><gtr:piContribution>Comparison and validation of different stem cell differentiation protocols to obtain different neuronal cell types</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2008-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Douglas Connect</gtr:collaboratingOrganisation><gtr:country>Switzerland, Swiss Confederation</gtr:country><gtr:description>ToxBank</gtr:description><gtr:id>B4433544-C34A-4D1D-A32C-929E5CCE109D</gtr:id><gtr:impact>Cross consotium collaboration on cell line quality control and poster preaetnations at SEURAT-1 meetings
Kohonen, P; Benfenati, E; Bower, D; Ceder, R; Crump, M; Cross, K; Grafstr&amp;ouml;m, R; Healey, L; Helma, C; Jeliazkova, N; Jeliazkov, V; Maggioni, S; Miller, S; Myatt, G; Rautenberg, M; Stacey, G; Willighagen, E; Wiseman, J; Hardy, B (2013) The ToxBank Data Warehouse: Supporting the Replacement of In Vivo Repeated Dose Systemic Toxicity Testing. Molecular Informatics. Special Issue: Advances in Computational Toxicology. 32; 47-63.
Public conference and workshop: Stem Cell Applications, Wellcome Trust, London, Nov 2015
Opentox workshop: Bridging strategies for stem cells, Rheinfelden, Germany, October 31st 2015.</gtr:impact><gtr:outcomeId>MWq6DKTUq83-1</gtr:outcomeId><gtr:partnerContribution>Overall construction of data warehouse and toxciology sections</gtr:partnerContribution><gtr:piContribution>Creation of biomaterials sections of data warehouse for the multiconsotium cluster SEURAT-1</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>International Stem Cell Forum (ISCF)</gtr:collaboratingOrganisation><gtr:country>Global</gtr:country><gtr:description>International Stem Cell Banking Initiative</gtr:description><gtr:id>4C4FB78A-8CF5-441A-940E-49BBD3C8029A</gtr:id><gtr:impact>Consensus on best practice in the procurement banking testing and release of hESC lines (2009)
Andrews et al., (2015) Points to consider in the development of seed stocks of pluripotent stem cells for clinical applications. Regenerative Medicine. 10 (02s) doi: 10.2217/RME.14.93 
Stacey GN. (in press) Stem Cell Banking: A Global Overview. In: Stem Cell Banking: Methods and Protocols, Human Press, Springer Science +Business Media LLC, USA.</gtr:impact><gtr:outcomeId>WRmpnyo4P5u-1</gtr:outcomeId><gtr:partnerContribution>Consensus on best opractice (Andrews et al., Stem Cell Reports and Revs , Dec 2009). Stem cell bank self evaluation procedures (Stacey et al., Cell Stem Cell 2013). managing research data from stem cell lines (Isasi et al., Regen Med, 2012).</gtr:partnerContribution><gtr:piContribution>Led coordination of scientists and regulators from more than 20 countries and compiled reports and draft publications</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Edinburgh stem cell public awareness day</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>Regional</gtr:geographicReach><gtr:id>1792BCB9-437A-4658-9131-6B2A710BD706</gtr:id><gtr:impact>c50 attendees at an open public meeting to discuss stem cell research and the role of UKSCB

No further action</gtr:impact><gtr:outcomeId>in5KwkzZ3zA</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2011</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>UKSCB Open Forum</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>417A0BA5-D2D7-4E45-92D7-6351A5778A75</gtr:id><gtr:impact>c50-100 attendees at UK National Stem Cell Network sessions run by UKSCB latterly run as a technical forum to engage researchers in the hESC and iPSC field

New contacts re potential UKSCB users</gtr:impact><gtr:outcomeId>r8cHSymgHU9</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2009,2010,2013,2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Presentations at scientific meetings</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>DE8CBA23-B73B-4FC4-85D2-703C942C9C7F</gtr:id><gtr:impact>Presentations more numerous than can be listed here. c30-50 presetnations per year at various scientific meetings including International Society for Stem Cell Reseaerch, UK Nat Stem Cell Network, MRC and BBSRC grant holders meetings, commercial conferences. Summaries given in Annual Reports available of UKSCB website

Ongoing invitations to attend scientific meetings</gtr:impact><gtr:outcomeId>ir5ZxqC5p1h</gtr:outcomeId><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Public/other audiences</gtr:primaryAudience><gtr:year>2006,2007,2008,2009,2010</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>480718</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Alternative testing cluster SEURAT-1 (Scr&amp;amp;Tox)</gtr:description><gtr:end>2015-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>335024ED-E38F-4214-BC0A-17C191421294</gtr:id><gtr:outcomeId>hjs94bt6E950</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>398223</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>International Stem Cell Forum</gtr:description><gtr:end>2015-07-02</gtr:end><gtr:fundingOrg>International Stem Cell Forum (ISCF)</gtr:fundingOrg><gtr:id>87E16096-F49B-407A-9845-4D66BAF35AE3</gtr:id><gtr:outcomeId>nGS7K6vdtDf0</gtr:outcomeId><gtr:sector>Academic/University</gtr:sector><gtr:start>2007-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>126000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Seventh Framework Programme (FP7)</gtr:department><gtr:description>EC FP7 ESNATS</gtr:description><gtr:end>2013-09-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>E5CE2B99-A720-4265-804E-1174B0790734</gtr:id><gtr:outcomeId>CsCuY2BD3Es0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2008-03-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>251697</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Alternative testing cluster SEURAT-1 (Toxbank)</gtr:description><gtr:end>2016-12-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>82737BE5-A93A-4DBF-A4F4-F189EC2BB071</gtr:id><gtr:outcomeId>Cs18ZXfL3890</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2011-01-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>75000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>TSB Regenerative medicine programme - Tools and technologies</gtr:description><gtr:fundingOrg>Technology Strategy Board (TSB)</gtr:fundingOrg><gtr:id>72256EF0-0BCE-4851-AA17-F5D1AD418D8A</gtr:id><gtr:outcomeId>Wg6Aw8LVdXX</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-09-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>190000</gtr:amountPounds><gtr:country>European Union (EU)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>hESCreg II</gtr:description><gtr:end>2015-05-02</gtr:end><gtr:fundingOrg>European Commission</gtr:fundingOrg><gtr:id>D8CFDBF2-820F-4143-A635-B496E82F4403</gtr:id><gtr:outcomeId>RbyUNxEq7wT</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2013-05-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>13005</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>TSB Regenerative medicine programme - Tools and technologies</gtr:description><gtr:end>2014-10-02</gtr:end><gtr:fundingOrg>Technology Strategy Board (TSB)</gtr:fundingOrg><gtr:fundingRef>101105</gtr:fundingRef><gtr:id>713AA8C6-7EBE-4640-887F-E94494E1DC9A</gtr:id><gtr:outcomeId>DQsu2DnGcdL</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2012-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>24582</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Tools</gtr:description><gtr:end>2011-03-02</gtr:end><gtr:fundingOrg>Technology Strategy Board (TSB)</gtr:fundingOrg><gtr:id>F32B68F4-E3FD-4E74-ACEB-73119BE52D51</gtr:id><gtr:outcomeId>ktmariqJsMd0</gtr:outcomeId><gtr:sector>Public</gtr:sector><gtr:start>2010-04-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>National Clinical hESC Forum</gtr:description><gtr:geographicReach>Europe</gtr:geographicReach><gtr:id>60487747-4FAA-4808-B894-E2B8AA210D5D</gtr:id><gtr:impact>Providing best practice guidance for procurment of tissues, processing and testing for development of clinical grade hESC lines
Interaction with HTA HFEA and MHRA has supported a UK proposal for a change in the EU Tissues and Cells Directive in 2012</gtr:impact><gtr:outcomeId>TWAyyBqN4qi</gtr:outcomeId><gtr:type>Membership of a guidance committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>hESCreg EC database as an EC tool to register ethically sourced hESC and hiPSC lines</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>763FE159-E4A8-4A4D-BF9F-16F2546C1036</gtr:id><gtr:impact>Provided listing of international lines proposed for use in EC funded programmes
This site is used by ECommssion to highlight hESC lines considered acceptable for use in EC funded research 
From 2014 registration on website is likely to be a prerequisite for use of lines in EC funded projects
Project has been funded again from January 2016 for 5years</gtr:impact><gtr:outcomeId>SuZGDTZUsLj</gtr:outcomeId><gtr:type>Membership of a guideline committee</gtr:type><gtr:url>http://www.hescreg.eu/</gtr:url></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>Novel preservation equipment for clean rooms</gtr:description><gtr:id>580327B0-9175-417C-BBF5-73A03143D53B</gtr:id><gtr:impact>Early development none as yet</gtr:impact><gtr:outcomeId>aRCUrVEykmV</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Asymptote</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:description>Enrichment of viability in cell therapy products</gtr:description><gtr:id>ABDD14D0-5D41-4CFD-A54C-7614BBCCF0A6</gtr:id><gtr:impact>Early devt yet to have impact</gtr:impact><gtr:outcomeId>HYHgoHkrJNP</gtr:outcomeId><gtr:stage>Initial development</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Apopro</gtr:title><gtr:type>Support Tool - For Medical Intervention</gtr:type><gtr:yearDevCompleted>2012</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>MRC-5 bank established in UKSCB cleanroom facilities</gtr:description><gtr:id>4E8DAC84-C095-4CEB-A69D-358D051014DA</gtr:id><gtr:impact>Cells with safe history of use inn vaccine manufacture made available to multiple groups for cell therapy development.</gtr:impact><gtr:outcomeId>GWaWHw3y5VM</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>MRC-5 feeder cells for cell therapy</gtr:title><gtr:type>Cell line</gtr:type><gtr:yearFirstProvided>2007</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Banks of ethically sourced and quality controlled humna stem cell lines made available for public research and commercial development</gtr:description><gtr:id>A3EDE977-FC87-448F-A597-E1C13CDF7457</gtr:id><gtr:impact>Supporting research projects on stem cells for toxicology and and research in c80 other reserch organisations</gtr:impact><gtr:outcomeId>dRsNMV2JQGe</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>human stem cell banks</gtr:title><gtr:type>Cell line</gtr:type><gtr:url>http://www.ukstemcellbank.org.uk</gtr:url><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Well documented source of 3T3 cells provided for use by skin engraftment andf limbal stem cell transplant groups in UK</gtr:description><gtr:id>758FD7F2-BEDA-4C81-8310-2C3C13C3EEC9</gtr:id><gtr:impact>Central source of qualified cells provided for UK health services at request of Department of Health
Now under negotiation of agreements to permit International supply</gtr:impact><gtr:outcomeId>CnjrWGKfsji</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>Bank of 3T3 feeder cells for celltherapy</gtr:title><gtr:type>Cell line</gtr:type><gtr:url>http://www.nibsc.org/uk_stem_cell_bank/cell_lines/mefs.aspx</gtr:url><gtr:yearFirstProvided>2006</gtr:yearFirstProvided></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>Preparation of mouse embryonic fibroblasts for use in culture of stem cell lines Marketed as QMEFs</gtr:description><gtr:id>247C8AB7-F12F-4C57-9886-B6760F14E2FB</gtr:id><gtr:impact>It provides reliable seed stocks of feeder cells for routine use in stem cell resarch which have been quaiified on a range of hESC lines</gtr:impact><gtr:outcomeId>i8UFEV7pQQy</gtr:outcomeId><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>QMEF service</gtr:title><gtr:type>Technology assay or reagent</gtr:type><gtr:url>http://www.ukstemcellbank.org.uk</gtr:url><gtr:yearFirstProvided>2012</gtr:yearFirstProvided></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs><gtr:spinOutOutput><gtr:companyName>Asymptote</gtr:companyName><gtr:description>Developing novel cryopreservation devices</gtr:description><gtr:id>AB5BB102-4B90-49AF-BB52-0B88D54F2D9B</gtr:id><gtr:impact>UKSCB carrying out qualification expts with stem cells</gtr:impact><gtr:outcomeId>54639d7363ee14.06280674</gtr:outcomeId><gtr:url>http://www.cambridgenetwork.co.uk/directories/companies/2486/?atoz=A</gtr:url></gtr:spinOutOutput><gtr:spinOutOutput><gtr:companyName>Apropo</gtr:companyName><gtr:description>Developing equipment to optimise preservation and viability of cell therapy products</gtr:description><gtr:id>C2A6DDDD-79C3-40EB-B77C-0C16E746E6C8</gtr:id><gtr:impact>UKSCB supported on evaluation of equiment utility</gtr:impact><gtr:outcomeId>54639c2a6a6095.47597068</gtr:outcomeId><gtr:url>http://www.companieslist.co.uk/SC421400-coolgenics-limited</gtr:url><gtr:yearCompanyFormed>2012</gtr:yearCompanyFormed></gtr:spinOutOutput></gtr:spinOutOutputs></gtr:output><gtr:publications><gtr:publication><gtr:id>181049BA-F9B5-482D-A697-C1C871A557C8</gtr:id><gtr:title>Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage.</gtr:title><gtr:parentPublicationTitle>Nature biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/ac8dda101d738f96423f3e6d8bd9cce1"><gtr:id>ac8dda101d738f96423f3e6d8bd9cce1</gtr:id><gtr:otherNames>International Stem Cell Initiative</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1087-0156</gtr:issn><gtr:outcomeId>oC2e5hbfDSJ</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>90DBEC5D-3EE1-4E10-9145-7F027AC226C8</gtr:id><gtr:title>Putting cells to sleep for future science.</gtr:title><gtr:parentPublicationTitle>Nature biotechnology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fde166f056eed9bd4f9f9f3385e39c3c"><gtr:id>fde166f056eed9bd4f9f9f3385e39c3c</gtr:id><gtr:otherNames>Stacey GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1087-0156</gtr:issn><gtr:outcomeId>545fdefa58e069.75210196</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E364EE26-B9D7-4FE0-844B-C38C278C3BCC</gtr:id><gtr:title>A call for standardized naming and reporting of human ESC and iPSC lines.</gtr:title><gtr:parentPublicationTitle>Cell stem cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/4280060ec3591374d9bd63c90e47433e"><gtr:id>4280060ec3591374d9bd63c90e47433e</gtr:id><gtr:otherNames>Luong MX</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1875-9777</gtr:issn><gtr:outcomeId>LMmssCvcLVK</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>02C5B163-9E0E-45C7-A25E-8E0D60E36634</gtr:id><gtr:title>Identifiability and privacy in pluripotent stem cell research.</gtr:title><gtr:parentPublicationTitle>Cell stem cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67b18894c79fff8938127c2039f795e3"><gtr:id>67b18894c79fff8938127c2039f795e3</gtr:id><gtr:otherNames>Isasi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>1875-9777</gtr:issn><gtr:outcomeId>545fdefaa548b0.19561105</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>202DEAF5-C842-4CCD-B342-53BBE1AE2828</gtr:id><gtr:title>Reconsidering pluripotency tests: do we still need teratoma assays?</gtr:title><gtr:parentPublicationTitle>Stem cell research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/324de1609734b204ec0966f18d42ee44"><gtr:id>324de1609734b204ec0966f18d42ee44</gtr:id><gtr:otherNames>Buta C</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1873-5061</gtr:issn><gtr:outcomeId>pm_16683_23_23611953</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5DB74B3-27BE-456A-8F1C-52BB22DAC99F</gtr:id><gtr:title>Current developments in cell culture technology.</gtr:title><gtr:parentPublicationTitle>Advances in experimental medicine and biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e69578abee6346451f3ce22569cc168d"><gtr:id>e69578abee6346451f3ce22569cc168d</gtr:id><gtr:otherNames>Stacey G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0065-2598</gtr:issn><gtr:outcomeId>pm_16683_23_22437809</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2E99C017-5F7D-47DC-94A2-5358E87F6D6F</gtr:id><gtr:title>Disclosure and management of research findings in stem cell research and banking: policy statement.</gtr:title><gtr:parentPublicationTitle>Regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/67b18894c79fff8938127c2039f795e3"><gtr:id>67b18894c79fff8938127c2039f795e3</gtr:id><gtr:otherNames>Isasi R</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1746-0751</gtr:issn><gtr:outcomeId>pm_16683_23_22594334</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>967CE197-E573-4399-BD98-3DACD4357952</gtr:id><gtr:title>The ToxBank Data Warehouse: Supporting the Replacement of In Vivo Repeated Dose Systemic Toxicity Testing.</gtr:title><gtr:parentPublicationTitle>Molecular informatics</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/68506e383f55c89e7cab9b57fee6c3bf"><gtr:id>68506e383f55c89e7cab9b57fee6c3bf</gtr:id><gtr:otherNames>Kohonen P</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1868-1743</gtr:issn><gtr:outcomeId>tKw2xmG6UGV</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3FE93324-FD49-4036-B826-7ED7A89974C2</gtr:id><gtr:title>Stem cell banks: preserving cell lines, maintaining genetic integrity, and advancing research.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/270e04dc44ff42c8eb3fea2cf144d86c"><gtr:id>270e04dc44ff42c8eb3fea2cf144d86c</gtr:id><gtr:otherNames>Healy L</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>UP1v3NJPVEm</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>667D683A-17B1-459F-BACC-6EE0747D4C34</gtr:id><gtr:title>Standards can help bring products to market.</gtr:title><gtr:parentPublicationTitle>Bioprocess International</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/981f4c9c544a883b0d076fa331766fc2"><gtr:id>981f4c9c544a883b0d076fa331766fc2</gtr:id><gtr:otherNames>Sheridan</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>sRaYWWvySMS</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>58852F5D-A293-4788-85C8-389B849FB78C</gtr:id><gtr:title>Host cells and cell banking.</gtr:title><gtr:parentPublicationTitle>Methods in molecular biology (Clifton, N.J.)</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fde166f056eed9bd4f9f9f3385e39c3c"><gtr:id>fde166f056eed9bd4f9f9f3385e39c3c</gtr:id><gtr:otherNames>Stacey GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2011-01-01</gtr:date><gtr:issn>1064-3745</gtr:issn><gtr:outcomeId>Up7HcPTom17</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>F5374900-48C7-4091-9A0B-3E7F3286C118</gtr:id><gtr:title>The procurement of cells for the derivation of human embryonic stem cell lines for therapeutic use: recommendations for good practice.</gtr:title><gtr:parentPublicationTitle>Stem cell reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f0ae23803e6e96e9fac7081387c099d5"><gtr:id>f0ae23803e6e96e9fac7081387c099d5</gtr:id><gtr:otherNames>Murdoch A</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1550-8943</gtr:issn><gtr:outcomeId>eMmMSKvnFtj</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>DEDE2E6E-125A-4289-8F2A-186F1B4096AB</gtr:id><gtr:title>Banking human induced pluripotent stem cells: lessons learned from embryonic stem cells?</gtr:title><gtr:parentPublicationTitle>Cell stem cell</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/fde166f056eed9bd4f9f9f3385e39c3c"><gtr:id>fde166f056eed9bd4f9f9f3385e39c3c</gtr:id><gtr:otherNames>Stacey GN</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>1875-9777</gtr:issn><gtr:outcomeId>pm_16683_23_24094320</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>2AF6F35C-EEB2-405C-9B31-5175F75CB2BE</gtr:id><gtr:title>Banking stem cells for research and clinical applications.</gtr:title><gtr:parentPublicationTitle>Progress in brain research</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e69578abee6346451f3ce22569cc168d"><gtr:id>e69578abee6346451f3ce22569cc168d</gtr:id><gtr:otherNames>Stacey G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0079-6123</gtr:issn><gtr:outcomeId>pm_16683_23_23195414</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>E4E8F899-6CA9-4186-8E8D-021A68E2D688</gtr:id><gtr:title>Social science in a stem cell laboratory: what happened when social and life sciences met.</gtr:title><gtr:parentPublicationTitle>Regenerative medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e69578abee6346451f3ce22569cc168d"><gtr:id>e69578abee6346451f3ce22569cc168d</gtr:id><gtr:otherNames>Stacey G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1746-0751</gtr:issn><gtr:outcomeId>pm_16683_23_22168502</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>0DB8565D-8F7B-4046-B335-D089C6D57BD9</gtr:id><gtr:title>Global solutions to the challenges of setting up and managing a stem cell laboratory.</gtr:title><gtr:parentPublicationTitle>Stem cell reviews</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/2a85373fb057a9669fdce235db9290bc"><gtr:id>2a85373fb057a9669fdce235db9290bc</gtr:id><gtr:otherNames>Inamdar MS</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1550-8943</gtr:issn><gtr:outcomeId>pm_16683_23_22038333</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>37FC9A0E-B7BD-4865-8B65-3DE894092099</gtr:id><gtr:title>Sourcing and using stem cell lines for radiation research: Potential, challenges and good stem cell culture practice.</gtr:title><gtr:parentPublicationTitle>International journal of radiation biology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/e69578abee6346451f3ce22569cc168d"><gtr:id>e69578abee6346451f3ce22569cc168d</gtr:id><gtr:otherNames>Stacey G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>0955-3002</gtr:issn><gtr:outcomeId>pm_16683_23_22823510</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>B30EDE8F-5EDA-4AEC-B21B-ECF410A4B8D5</gtr:id><gtr:title>Regenerative Medicine: Stem Cells and the Liver</gtr:title><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/17c0e982e1dfa1b9804c496d940a6e70"><gtr:id>17c0e982e1dfa1b9804c496d940a6e70</gtr:id><gtr:otherNames>deSousa</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:outcomeId>KU9ozWzgfTT</gtr:outcomeId></gtr:publication><gtr:publication><gtr:id>3EEBBD49-F1B7-42C3-9934-22D3139E5D15</gtr:id><gtr:title>Standardization of pluripotent stem cell cultures for toxicity testing.</gtr:title><gtr:parentPublicationTitle>Expert opinion on drug metabolism &amp; toxicology</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.ukri.org:80/person/f1efdfe8843a84dd63593815dac3a525"><gtr:id>f1efdfe8843a84dd63593815dac3a525</gtr:id><gtr:otherNames>Pistollato F</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2012-01-01</gtr:date><gtr:issn>1742-5255</gtr:issn><gtr:outcomeId>pm_16683_23_22248265</gtr:outcomeId></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G1001045</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>F3822669-BB5A-4BB4-BAE0-DCB9DE36E092</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Generic Health Relevance</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>1A41A859-2076-46E6-B80F-CE4E1E8EDC1D</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>1.5  Resources and infrastructure (underpinning)</gtr:text></gtr:researchActivity><gtr:researchActivity><gtr:id>A056411B-DD7A-4062-BE33-7849FBC9BFA7</gtr:id><gtr:percentage>50</gtr:percentage><gtr:text>5.9  Resources and infrastructure (development of treatments)</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>